ft819
ft819: sourced relationships with 1 company · 3 clinical trials tracked.
ft819 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could ft819 → FATE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| FATE THERAPEUTICS INC (FATE) Lymphoma, B-Cell; Antineutrophilic Cytoplasmic Antibody (ANC… | Phase 2 |
Clinical Trial Registry Records (3)
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Refractory Moderate-to-Severe Systemic Lupus Erythematosus With Lupus Nephritis (RECLAIM-LN)
Primary endpoint: Complete Renal Response (CRR) at Week 26
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs)
A Phase I Study of FT819 in Subjects With B-cell Malignancies
Primary endpoint: Incidence and nature of dose-limiting toxicities within each dose level cohort
Frequently asked questions
Which companies have sourced relationships with ft819?
ft819 has dated SEC/FDA relationship records for FATE THERAPEUTICS INC.
How many clinical trials involve ft819?
BioSniper tracks 3 clinical trials involving ft819.